Category Archives: FDA Stem Cell Trials

CBLB502 was granted Fast Track and Orphan Drug designations from the FDA for reducing the risk of or preventing death following total body irradiation during or after radiation disaster. The FDA Fast Track program is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Such programs include expanded communications (both verbal and written), rolling BLA submission and reviews, priority review (6 month action date instead of 10 month action date) and accelerated drug approval (approval on the basis of a surrogate endpoint). View post: CBLI Breaking News … Continue reading →

A Decade with the Human Genome Sequence: Charting a Course for Genomic Medicine NHGRI hosted a day-long scientific symposium on Friday, Feb. 11, 2011, 8:30 am - 5:00 pm at the Ruth L. Here is the original post: Anticipating the Next Decade of the Genome - Francis Collins, Director of NIH … Continue reading →

Listen in as leading pediatric neurosurgeon Dr. Baumgartner discusses the future potential of regenerative medicine. Cord blood stem cells are being used today to treat blood disorders and certain cancers. Follow this link: What is Cord Blood Banking? The Medical Potential of Newborn Stem Cells … Continue reading →

CNN's Dr. Sanjay Gupta reports on a new stem cell clinical trial that is making history. More: Stem cell medical breakthrough? … Continue reading →

Yu-Chong Tai, Director, Caltech Micro Machining Laboratory, California Institute of Technology discusses research in the use of neural implants such pacemakers and electronic cochlear implants. Dr. Tai reviews progress on the next generation of implants which must be miniature, flexible, and highly functional for muscular, retinal, cortical, and spinal use. Continued here: NIST Colloquium Series: Next Generation Neural Implants … Continue reading →

Embryonic stem cells have the potential to help treat 70 or more diseases, but developing those new therapies will take time. Alan Lewis is president and CEO of Novocell, a La Jolla-based company that has been developing a potential therapy for diabetes. Novocell has a CIRM grant to assemble a team of researchers who will accelerate the time it takes to get that potential therapy to the FDA for clinical trials. Excerpt from: Alan Lewis: Embryonic Stem Cell Therapies for diabetes … Continue reading →

Part one of an interview with NeuroPace's Dr. Martha Morrell by Epilepsy Therapy Project's Joyce Kramer about a new treatment option for epilepsy that is designed to detect abnormal electrical activity in the brain and deliver small amounts of electrical stimulation to suppress the abnormal activity before any seizure symptoms occur. The treatment, known as responsive neurostimulation, builds upon established neurostimulation technology that is FDA approved to treat Parkinson's disease and Essential Tremor More: New Epilepsy Treatment Under Study For Seizures - Part 1 … Continue reading →

Dr Lanza of ACT explains upcomming therpaies of blood generation and vascular repair using stem cells. Their cell were extracted from a single cell without destroying the embryo More here: ACT - Dr Lanza - Hermangioblast program - Advanced cell technology … Continue reading →

Bill Caldwell, Chairman Read the original: Bill Caldwell, Chairman … Continue reading →

Company Overview Advanced Cell Technology, Inc. (OTCBB:ACTC -- News) is a biotechnology company that specializes in the development of cellular therapies for the treatment of rare and common diseases that impact millions of people worldwide. Read the original post: Advanced Cell Technology OneMedForum 2011 … Continue reading →